R&D Costs and Productivity in Biopharmaceuticals
Citation
Scherer, F.M. 2011. R&D Costs and Productivity in Biopharmaceuticals. HKS Faculty Research Working Paper Series RWP11-046, John F. Kennedy School of Government, Harvard UniversityAbstract
This article characterizes the activities required to launch a new pharmaceutical molecule into the market, summarizes studies that have attempted to pinpoint the research and development costs incurred per approved new molecule, and analyzes the various critiques levied against published R&D cost estimates. It finds that by any reckoning, R&D costs per approved molecule have risen sharply over time, most likely at a rate of approximately 7 percent per year after stripping out the effects of general economic inflation.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:5688848
Collections
- HKS Faculty Scholarship [762]
Contact administrator regarding this item (to report mistakes or request changes)